Headquartered in Durham, NC·Fiscal year ends December·NASDAQ: HUMA·humacyte.com
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing and manufacturing universally implantable, bioengineered human tissues at commercial scale.
Its lead product, Symvess, is an acellular tissue engineered vessel (ATEV). The FDA approved it in December 2024 for adults who need a vascular conduit for extremity arterial injury, when urgent revascularization is needed to avoid limb loss and autologous vein graft is not feasible. Symvess generates the company's product revenue and is sold to hospitals; 49 hospitals had ordered it as of September 30, 2026.
The ATEV is also in late-stage clinical development for:
- Arteriovenous (AV) access in hemodialysis, with a supplemental BLA planned for November 2026 based on the V007, V012 and a third Phase 3 study.
- Peripheral artery disease.
The company's coronary tissue engineered vessel (CTEV) has entered a first-in-human Phase 2a study in coronary artery bypass grafting. Preclinical programs include pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.
Regulatory designations:
- The 6mm ATEV for dialysis access was the first product candidate to receive RMAT designation and also holds Fast Track designation.
- The vascular trauma and advanced PAD indications also hold RMAT designations.
- The ATEV has priority designation for vascular trauma from the U.S. Secretary of Defense. Updated
On April 18th, 24/7 Wall Street alerted investors to a recent stock purchase by Alabama Senator Tommy Tuberville of a penny stock named Humacyte (Nasdaq: HUMA). We track Congressional trades as sitting members…
Tommy Tuberville, a Republican Senator from the state of Alabama, disclosed 19 new stock trades on April 15th, and one trade in particular is causing big movements in the underlying stock. Tuberville…
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing and manufacturing universally implantable, bioengineered human tissues at commercial scale. Its lead product, Symvess, is an acellular tissue engineered vessel (ATEV).
What is the HUMA stock price target?
The Wall Street consensus 12-month price target for HUMA is $1.64.